for Cancer

ACTDrug™ is the most efficient and cost-effective cancer genome sequencing platform. With small amount of DNA samples, ACTDrug can scan thousands of mutational hotspots to evaluate the mutational status for widely used targeted anticancer drugs.

207 amplicons for 50 important oncogenes and tumor suppressor genes, 1,636 COSMIC cancer hotspots are covered.

Covering 31 oncogenes, e.g. EGFR, KARS, BRAF, and 19 tumor suppressor genes, e.g. TP53, RB1, APC, for selection of cancer therapy. Actionable drugs including 32 US FDA approved cancer targeted therapies, and 67 investigational drugs.

Our report generating engine utilizes standard reference database, in-house sequencing database, and manually curated drug-gene interaction database to achieve a comprehensive and therapeutically-relevant interpretation. Results are presented in a custom-designed graphic format to deliver intuitive and publication-ready reports.

Specific

Results and Statistical Analysis

Clinical Research Data:

• Individual sample report
  1. Sequencing QC report
  2. Variant alteration description
• Project report
  1. Mutation pattern by project cohort
  2. Distribution of sequence variants
  3. Distribution of non-synonymous mutation by sample
  4. Signaling pathway involving variants
  5. Comparing mutation spectrum of 5 selected genes with TCGA data

Statistical Results:

• Sample > 40
  1. Group-wise variant comparison
• Sample > 40, survival data available
  1. Kaplan-Meier analysis (including log-rank test)
  2. Cox Regression analysis (including hazard ratio)

Order Service

• Getting Started

Download

• ACTGenomics Brochure